2018年5月发邮件给香港医生：
what about Vemlidy(TAF，替诺福韦艾拉酚胺富马酸)是一种新型核苷类逆转录酶抑制剂(NRTI)，该药是已上市药物Viread(替诺福韦酯，TDF，在日本由葛兰素史克销售)的升级版。在临床试验中，TAF已被证明在低于Viread十分之一剂量时，就具有非常高的抗病毒疗效，同时具有更好的安全性，可改善肾功能和骨骼安全参数。
In fact for obtaining new prescription, I recommend Vemlidy now. This is basically produced by the same company, but at a better formulation, and less side effect.
Most patient actually switch, and also because the price was similar (and Viread did not reduce in price !).
The price of Vemlidy will be estimated as follow: HK$ 2490 per month; or 29880 per year, and I shall keep the previous price for Ms Li.; that will be $ 27390 for 1 year.